Ads
related to: pcsk9 inhibitors for cholesterol reduction- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Co-Pay Program
Resources
to Support Your Patients
- Trial Results
See Clinical Data
and Trial
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Request Samples
Get patients started
with a 14-day sample
- Patient Identification
View a Patient Profile
to Learn More
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
The most recent guidelines for cholesterol management from the American Heart Association and American College of Cardiology now provide guidance for when PCSK9 inhibitors should be considered, particularly focusing on cases in which maximally tolerated statin and ezetimibe fail to achieve goal LDL reduction.
Bococizumab (USAN; [1] development code RN316 [2]) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. [3] Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation; its inhibition thereby enhances the liver 's ability to remove LDL-C , often colloquially referred to as "bad" cholesterol , from the blood.
VERVE-101 and VERVE-102 are an experimental gene therapy developed by Verve Therapeutics that targets the PCSK9 gene and is intended to reduce blood cholesterol levels. It works on the same protein as the cholesterol-lowering drugs known as PCSK9 inhibitors but, unlike them, is permanent.
Bile acid sequestrants may cause gastrointestinal problems and may also reduce the absorption of other drugs and vitamins from the gut. Ezetimibe is a selective inhibitor of dietary cholesterol absorption. Lomitapide is a microsomal triglyceride transfer protein inhibitor. PCSK9 inhibitors [3] [4] are monoclonal antibodies for refractory
In July 2015, the FDA approved alirocumab as a second-line treatment to lower LDL cholesterol for adults who have hereditary high cholesterol and people with atherosclerosis who require additional lowering of LDL cholesterol when diet and statin treatment have not worked. [7] This was the first approval of a PCSK9 inhibitor. [7]
Ads
related to: pcsk9 inhibitors for cholesterol reduction